Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Remdesivir for the Treatment of Covid-19 — Final Report
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Avian influenza A (H5N1) infection in humans.
The writing committee consisted of the following: John H. Beigel, M.D., National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.; Jeremy Farrar, D.Phil.,…
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
The phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein in healthy adults found it induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100- μg dose in a phase 3 vaccine trial.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
A small number of adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers revealed immunogenicity and safety concerns.
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
This Ebola vaccine candidate elicited anti‐Ebola antibody responses and these results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses.
WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus
Transparent Development of the WHO Rapid Advice Guidelines
A systematic, transparent approach used by the World Health Organization to develop rapid advice guidelines in response to requests from member states confronted with uncertainty about the pharmacological management of avian influenza A (H5N1) virus infection is described.